CVRx (CVRX) Set to Announce Quarterly Earnings on Tuesday

CVRx (NASDAQ:CVRX) will announce its earnings results after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

CVRx (NASDAQ:CVRX) last issued its earnings results on Thursday, January 25th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.11. The business had revenue of $11.31 million for the quarter, compared to analyst estimates of $10.90 million. CVRx had a negative return on equity of 47.30% and a negative net margin of 104.85%. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Price Performance

CVRX stock opened at $14.69 on Friday. The stock has a market cap of $317.23 million, a price-to-earnings ratio of -7.42 and a beta of 1.29. CVRx has a fifty-two week low of $9.27 and a fifty-two week high of $33.13. The company has a quick ratio of 12.86, a current ratio of 14.25 and a debt-to-equity ratio of 0.38. The business has a 50 day moving average price of $18.91 and a 200 day moving average price of $20.96.

Insiders Place Their Bets

In other CVRx news, insider Paul Verrastro sold 2,545 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $21.91, for a total value of $55,760.95. Following the completion of the sale, the insider now owns 2,455 shares in the company, valued at $53,789.05. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Paul Verrastro sold 2,545 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $21.91, for a total value of $55,760.95. Following the completion of the transaction, the insider now owns 2,455 shares in the company, valued at approximately $53,789.05. The disclosure for this sale can be found here. 18.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CVRX. JPMorgan Chase & Co. boosted their price objective on shares of CVRx from $31.00 to $36.00 and gave the stock an “overweight” rating in a research report on Friday, January 26th. Piper Sandler lifted their price target on shares of CVRx from $21.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, January 26th.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.